Abstract
Sibutramine can produce dose-dependent increases in blood pressure and heart rate, especially during initial treatment. However, the cardiovascular effects of the drug are related to the weight loss achieved: patients who lose 5% or more of initial body weight have a reduction in blood pressure, which correlates with the degree of weight loss. Sibutramine does not exacerbate pre-existing controlled hypertension and treatment has been shown to be safe and effective in these patients. In clinical practice, it is important to observe the recommended exclusion criteria, to monitor blood pressure and heart rate and to adhere to the withdrawal criteria. This should enable the identification of those patients for whom sibutramine is not suitable while permitting the majority of patients to gain clinical benefit from treatment.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Narkiewicz, K. Sibutramine and its cardiovascular profile. Int J Obes 26 (Suppl 4), S38–S41 (2002). https://doi.org/10.1038/sj.ijo.0802218
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0802218
- Springer Nature Limited
Keywords
This article is cited by
-
Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects
Clinical Pharmacology & Therapeutics (2009)
-
Acute myocardial infarction associated with use of herbal medication
Clinical Research in Cardiology (2008)
-
Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials
International Journal of Obesity (2005)
-
Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study
Journal of Human Hypertension (2005)
-
Sibutramine and the sympathetic nervous system in obese humans
Clinical Autonomic Research (2005)